Francesc Estrany- Master of Pharmacy
- PhD Student at University of Barcelona
Francesc Estrany
- Master of Pharmacy
- PhD Student at University of Barcelona
Research in Cancer Gene Therapy: Oncolytic virus and immunotherapy. Looking for learning and connect with specialists.
About
4
Publications
392
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
4
Citations
Introduction
I Work in Cristina Fillat's Lab: Gene Therapy and Cancer (IDIBAPS)
We focus on oncolytic adenovirus attacking pancreatic cancer (PDAC), and inducing inmune response.
I have particular interest on transferent RNA (tRNA) pool alterations due to codon usage biases in transgenic virus.
Also, we are exploring the pro-tumorgenic cytokine Leukaemia inhibitory factor (LIF).
I am keen on sequencing techinques, qPCR, DNA recombination, cloning, RNA, viral infections, WB and tumoral in vivo models.
Current institution
Additional affiliations
September 2022 - present
Consorci Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS)
Position
- PhD Student
Description
- Studying immuno-Oncolytic Adenoviruses in Pancreatic ductal Adenocarcinoma (PDAC)
September 2022 - present
Education
September 2020 - September 2021
University of Barcelona
Field of study
- Research and Development of Drug Medicines
March 2020 - November 2021
University of Nebrija
Field of study
- Clinical Analysis Laboratory
September 2015 - September 2019
University of Barcelona
Field of study
- Biochemistry
Publications
Publications (4)
🚨📢 KPC-I: A New Murine Model for Oncolytic Adenovirus Research
In our study, we demonstrate that KPC-I pancreatic cancer cells, derived from genetically engineered mice, are permissive to human adenovirus replication — a key limitation that has long hindered preclinical evaluation of oncolytic virotherapy in immunocompetent models.
🧬 Compared to...
This is the Supplementary Data regarding the Journal article: "KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis"
Oncolytic adenoviral therapy is a promising approach for pancreatic cancer treatment. However, the limited capacity of murine cells to produce infectious viral progeny precludes the full evaluation of the virotherapy in a suitable immunocompetent mouse model. Here, we report that the murine KPC-I cell line, established from pancreatic tumors develo...
PROTACs (proteolysis-targeting chimeras) are innovative molecules ⚗ that can induce the degradation of a protein of interest via the natural ubiquitin-proteasome system 🗑. They are bifunctional, thus can bind both protein of interest (ligand) and reclute the E3-ubiquitin ligase enzyme.
We dealed with a PROTAC compound (ALT-PG2) targeting soluble e...
